An adjustable, safe and highly protective live-attenuated SARS-CoV-2 vaccine based on large-scale one-to-stop codon modifications

Martin Beer(Institute of Virology of the Slovak Academy of Sciences), Volker Thiel(University of Bern), Nico Joël Halwe(Friedrich-Loeffler-Institut), Fabien Labroussaa(Université Claude Bernard Lyon 1), Marco P. Alves(University of Bern), Lisa Thomann(University of Bern), Angele Breithaupt(Friedrich-Loeffler-Institut), Sarah Ochsenbein(University of Bern), Llorenç Grau‐Roma(Universitat Autònoma de Barcelona), Kore Schlottau(Friedrich-Loeffler-Institut), Kimberly Schmied(University of Bern), Charaf Benarafa(University of Bern), Vladimir Cmiljanović(PIQUR Therapeutics (Switzerland)), Silvio Steiner(University of Bern), Lea Almeida(University of Bern), Joerg Jores(University of Bern), Adriano Taddeo(University of Bern), Güliz T. Barut(University of Bern), Annika Kratzel(University of Bern), Claudia Wylezich(Friedrich-Loeffler-Institut), Melanie Brügger(University of Bern), Nadine Ebert(University of Bern), Lorenz Ulrich(Friedrich-Loeffler-Institut), Bettina Salome Trüeb(University of Bern), Ann Kathrin Ahrens(Friedrich-Loeffler-Institut), Jacob Schön(Friedrich-Loeffler-Institut), Étori Aguiar Moreira(University of Bern), Christelle Devisme(University of Bern), Inês Berenguer Veiga(University of Bern), Tobias Britzke(Friedrich-Loeffler-Institut), Péter Túrós(University of Bern), Blandina Exteves(University of Bern), Philip V ́kovski, Donata Hoffmann(Friedrich-Loeffler-Institut), H. Stadler(University of Bern), Jenna N. Kelly(University of Bern)
Research Square
August 29, 2023
Cited by 0


Related Papers